Predictors of overall survival following extended radical resections for locally advanced and recurrent pelvic malignancies.


Journal

Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 27 10 2019
accepted: 15 05 2020
pubmed: 14 6 2020
medline: 29 6 2021
entrez: 14 6 2020
Statut: ppublish

Résumé

In an era of personalised medicine, there is an overwhelming effort for predicting patients who will benefit from extended radical resections for locally advanced pelvic malignancy. However, there is paucity of data on the effect of comorbidities and postoperative complications on long-term overall survival (OS). The aim of this study was to define predictors of 1-year and 5-year OS. Data were collected from prospective databases at two high-volume institutions specialising in beyond TME surgery for locally advanced and recurrent pelvic malignancies between 1990 and 2015. The primary outcome measures were 1-year and 5-year OS. A total of 646 consecutive extended radical resections were performed between 1990 and 2015. The majority were female patients (371, 57.4%) and the median age was 63 years (range 19-89 years). One-year OS, primary rectal adenocarcinoma had the best survival while recurrent colon cancer had the worse survival (p = 0.047). The 5-year OS between primary and recurrent cancers were 64.7% and 53%, respectively (p = 0.004). Poor independent prognostic markers for 5-year OS were increasing ASA score, cardiovascular disease, recurrent cancers, ovarian cancers, pulmonary embolus and acute respiratory distress syndrome. A positive survival benefit was demonstrated with preoperative radiotherapy (HR 0.55; 95% CI 0.4-0.75, p < 0.001). Patient comorbidities and specific complications can influence long-term survival following extended radical resections. This study highlights important predictors, enabling clinicians to better inform patients of the potential short- and long-term outcomes in the management of locally advanced and recurrent pelvic malignancy.

Identifiants

pubmed: 32533361
doi: 10.1007/s00423-020-01895-y
pii: 10.1007/s00423-020-01895-y
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

491-502

Références

Brunschwig A (1948) Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer 1(2):177–183
doi: 10.1002/1097-0142(194807)1:2<177::AID-CNCR2820010203>3.0.CO;2-A pubmed: 18875031
Brunschwig A, Daniel W (1960) Pelvic exenteration operations: with summary of sixty-six cases surviving more than five years. Ann Surg 151:571–576
doi: 10.1097/00000658-196004000-00018 pubmed: 13805389 pmcid: 1613585
Radwan RW, Jones HG, Rawat N, Davies M, Evans MD, Harris DA, Beynon J, Swansea Pelvic Oncology Group (2015) Determinants of survival following pelvic exenteration for primary rectal cancer. Br J Surg 102(10):1278–1284
doi: 10.1002/bjs.9841 pubmed: 26095525
Morley GW, Hopkins MP, Lindenauer SM, Roberts JA (1989) Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 74(6):934–943
pubmed: 2586960
Westin SN, Rallapalli V, Fellman B, Urbauer DL, Pal N, Frumovitz MM, Ramondetta LM, Bodurka DC, Ramirez PT, Soliman PT (2014) Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol 134(3):546–551
doi: 10.1016/j.ygyno.2014.06.034 pubmed: 25014540 pmcid: 4160382
Steffens D, Solomon MJ, Young JM, Koh C, Venchiarutti RL, Lee P, Austin K (2018) Cohort study of long-term survival and quality of life following pelvic exenteration. BJS Open 2(5):328–335
doi: 10.1002/bjs5.75 pubmed: 30263984 pmcid: 6156168
You YN, Skibber JM, Hu C-Y, Crane CH, Das P, Kopetz ES, Eng C, Feig BW, Rodriguez-Bigas MA, Chang GJ (2016) Improved long-term salvage potential of locally recurrent rectal cancer with evolving multimodality therapy. Br J Surg 103(6):753–762
doi: 10.1002/bjs.10079 pubmed: 26933792 pmcid: 5407413
Georgiou PA, Tekkis PP, Constantinides VA, Patel U, Goldin RD, Darzi AW, John Nicholls R, Brown G (2013) Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer. Eur J Cancer 49(1):72–81
doi: 10.1016/j.ejca.2012.06.025 pubmed: 23036847
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
doi: 10.1097/01.sla.0000133083.54934.ae pubmed: 15273542 pmcid: 15273542
Berrios-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR et al (2017) Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg 152(8):784–791
doi: 10.1001/jamasurg.2017.0904 pubmed: 28467526
Rahbari NN, Weitz J, Hohenberger W, Heald RJ, Moran B, Ulrich A, Holm T, Wong WD, Tiret E, Moriya Y, Laurberg S, den Dulk M, van de Velde C, Büchler MW (2010) Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery 147(3):339–351
doi: 10.1016/j.surg.2009.10.012 pubmed: 20004450
Wagenlehner FM, Pilatz A, Naber KG, Weidner W (2008) Therapeutic challenges of urosepsis. Eur J Clin Investig 38(Suppl 2):45–49
doi: 10.1111/j.1365-2362.2008.02008.x
Kreiner L (2018) Intra-abdominal collection: BMJ. Available from: https://bestpractice.bmj.com/topics/en-gb/996
Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, O'Callaghan C, Myint AS, Bessell E, Thompson LC, Parmar M, Stephens RJ, Sebag-Montefiore D, MRC CR07/NCIC-CTG CO16 Trial Investigators, NCRI Colorectal Cancer Study Group (2009) MRC CR07/NCIC-CTG CO16 Trial Investigators; NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373:821–828
doi: 10.1016/S0140-6736(09)60485-2 pubmed: 19269520 pmcid: 2668948
Nagtegaal ID, Quirke P (2008) What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26:303–312
doi: 10.1200/JCO.2007.12.7027 pubmed: 18182672
Wibe A (2002) Moller B; A national strategic change in treatment policy for rectal cancer—implementation of total mesorectal excision as routine treatment in Norway. Dis Colon Rectum 45:857–866
doi: 10.1007/s10350-004-6317-7 pubmed: 12130870
Ortiz H (2013) Impact of a multidisciplinary team training programme on rectal cancer outcomes in Spain. Color Dis 15:544–551
doi: 10.1111/codi.12141
West NP, Sutton KM, Ingeholm P, Hagemann-Madsen RH, Hohenberger W, Quirke P (2010) Improving the quality of colon cancer surgery through a surgical education program. Dis Colon Rectum 53:1594–1603
doi: 10.1007/DCR.0b013e3181f433e3 pubmed: 21178852
Khan MA (2015) Significance of R1 resection margin in colon cancer resections in the modern era. Color Dis 17:943–953
doi: 10.1111/codi.12960
Seymour MT, Morton D, on behalf of the International FOxTROT Trial Investigators (2019) FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol 37(15_suppl):3504–3350
doi: 10.1200/JCO.2019.37.15_suppl.3504
Ferenschild FTJ, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AMM, de Wilt JHW (2009) Total pelvic exenteration for primary and recurrent malignancies. World J Surg 33(7):1502–1508
doi: 10.1007/s00268-009-0066-7 pubmed: 19421811 pmcid: 2691931
Gannon CJ, Zager JS, Chang GJ, Feig BW, Wood CG, Skibber JM, Rodriguez-Bigas MA (2007) Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol 14(6):1870–1877
doi: 10.1245/s10434-007-9385-9 pubmed: 17406945
Kuhrt MP, Chokshi RJ, Arrese D, Martin EW Jr (2012) Retrospective review of pelvic malignancies undergoing total pelvic exenteration. World J Surg Oncol 10(1):110
doi: 10.1186/1477-7819-10-110 pubmed: 22703863 pmcid: 3465228
Klok FA, Zondag W, Kralingen KW, Dijk APJ, Tamsma JT, Heyning FH et al (2010) Patient Outcomes after Acute Pulmonary Embolism. Am J Respir Crit Care Med 181(5):501–506
doi: 10.1164/rccm.200907-1141OC pubmed: 19965808
White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ (2014) Age and cancer risk: a potentially modifiable relationship. Am J Prev Med 46(3 0 1):S7–S15
doi: 10.1016/j.amepre.2013.10.029 pubmed: 24512933 pmcid: 4544764
Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW (2005) Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55(3):231–240
doi: 10.1016/j.critrevonc.2005.04.008 pubmed: 15979890
Kong CH, Guest GD, Stupart DA, Faragher IG, Chan ST, Watters DA (2015) Colorectal preOperative Surgical Score (CrOSS) for mortality in major colorectal surgery. ANZ J Surg 85(6):403–407
doi: 10.1111/ans.13066 pubmed: 25823601
Janssen-Heijnen ML, Szerencsi K, van de Schans SA, Maas HA, Widdershoven JW, Coebergh JW (2010) Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10 years older without cardiovascular morbidity. Crit Rev Oncol Hematol 76(3):196–207
doi: 10.1016/j.critrevonc.2009.11.004 pubmed: 20036574
Tashakkor AY, Moghaddamjou A, Chen L, Cheung WY (2013) Predicting the risk of cardiovascular comorbidities in adult cancer survivors. Curr Oncol 20(5):e360–ee70
doi: 10.3747/co.20.1470 pubmed: 24155634 pmcid: 3805406
Des Guetz G (2010) Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 46:1049–1055
doi: 10.1016/j.ejca.2010.01.020 pubmed: 20138505
Bosset J-F (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123
doi: 10.1056/NEJMoa060829 pubmed: 16971718
Harris CA, Solomon MJ, Heriot AG, Sagar PM, Tekkis PP, Dixon L, Pascoe R, Dobbs BR, Frampton CM, Harji DP, Kontovounisios C, Austin KK, Koh CE, Lee PJ, Lynch AC, Warrier SK, Frizelle FA (2016) The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg 264(2):323–329
doi: 10.1097/SLA.0000000000001524 pubmed: 26692078
Lau YC, Jongerius K, Wakeman C, Heriot AG, Solomon MJ, Sagar PM, Tekkis PP, Frizelle FA (2019) Influence of the level of sacrectomy on survival in patients with locally advanced and recurrent rectal cancer. Br J Surg 106(4):484–490
doi: 10.1002/bjs.11048 pubmed: 30648734

Auteurs

Joseph C Kong (JC)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.

Oliver Peacock (O)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.

Peadar S Waters (PS)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia. peadarwaters@hotmail.com.

Tim Eglinton (T)

Colorectal Surgery Unit, Christchurch Hospital, Christchurch, New Zealand.

Satish K Warrier (SK)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.

Christopher Wakeman (C)

Colorectal Surgery Unit, Christchurch Hospital, Christchurch, New Zealand.

Frank A Frizelle (FA)

Colorectal Surgery Unit, Christchurch Hospital, Christchurch, New Zealand.

Alexander G Heriot (AG)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.

Jacob J McCormick (JJ)

Division of Cancer Surgery, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH